logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Malignant Neoplasms

    Medications for Malignant Neoplasms

    FiltersReset Filters
    13 results

    • diazoxide

      (Diazoxide)
      Par Pharmaceutical, Inc
      Usage: Diazoxide oral suspension is indicated for managing hypoglycemia due to hyperinsulinism, including conditions like inoperable islet cell tumors and certain pediatric disorders. It is used when other treatments fail or are not viable, both preoperatively and postoperatively for persistent hypoglycemia.

    • ethacrynate sodium

      (ETHACRYNATE SODIUM)
      Leading Pharma, LLC
      Usage: Ethacrynic acid is indicated for treating edema in conditions such as congestive heart failure, liver cirrhosis, and renal disease. It is also used for short-term management of malignancy-related ascites, idiopathic edema, and pediatric patients with specific heart conditions, particularly when rapid diuresis is needed.

    • ethacrynic acid

      (Ethacrynic acid)
      TRUPHARMA LLC
      Usage: Ethacrynic Acid Tablets are indicated for treating edema requiring potent diuresis, associated with conditions like congestive heart failure, liver cirrhosis, and renal disease. They are also used for managing ascites, idiopathic edema, and lymphedema, and for hospitalized pediatric patients with specific conditions. Intravenous forms are for rapid diuresis.

    • fludeoxyglucose

      (Fludeoxyglucose F-18)
      Biomedical Research Foundation of Northwest Louisiana
      Usage: Fludeoxyglucose F 18 Injection USP is indicated for PET imaging in oncology for assessing malignancy, in cardiology for evaluating heart function in coronary artery disease, and in neurology for identifying areas of abnormal glucose metabolism related to epileptic seizures.

    • fludeoxyglucose f 18

      (Fludeoxyglucose F 18)
      PETNET Solutions, Inc.
      Usage: Fludeoxyglucose F 18 Injection is used for PET imaging in oncology to assess glucose metabolism in malignancies, in cardiology to evaluate left ventricular function in coronary artery disease, and in neurology to identify abnormal glucose metabolism related to epileptic seizures.

    • fludeoxyglucose f 18

      (Fludeoxyglucose F-18)
      Jubilant DraxImage Inc., dba Jubilant Radiopharma
      Usage: Fludeoxyglucose F18 Injection is indicated for PET imaging in oncology to assess abnormal glucose metabolism in malignancy, in cardiology to identify myocardial glucose metabolism in coronary artery disease, and in neurology to locate abnormal glucose metabolism related to epileptic seizures.

    • fludeoxyglucose f 18

      (Fludeoxyglucose F-18)
      SOFIE Co.
      Usage: Fludeoxyglucose F18 Injection is indicated for PET imaging in oncology to evaluate malignancy, in cardiology to assess glucose metabolism in coronary artery disease, and in neurology to identify abnormal glucose metabolism related to epileptic seizures.

    • fludeoxyglucose f 18

      (Fludeoxyglucose F-18)
      Mayo Clinic
      Usage: Fludeoxyglucose F 18 Injection USP is indicated for PET imaging to assess abnormal glucose metabolism in oncology for malignancy evaluation, in cardiology for identifying reversible left ventricular dysfunction in coronary artery disease, and in neurology to locate abnormal glucose metabolism related to epileptic seizures.

    • fludeoxyglucose f-18

      (FLUDEOXYGLUCOSE F-18)
      Precision Nuclear, LLC
      Usage: Fludeoxyglucose F 18 Injection USP is indicated for PET imaging in oncology to assess glucose metabolism in malignancies, in cardiology for identifying left ventricular myocardium metabolism in coronary artery disease, and in neurology for locating abnormal glucose metabolism related to epileptic seizures.

    • fludeoxyglucose f18

      (Fludeoxyglucose F-18)
      Biomedical Research Foundation of Northwest Louisiana
      Usage: Fludeoxyglucose F 18 Injection is indicated for PET imaging in oncology to evaluate malignancies, in cardiology to identify residual glucose metabolism in coronary artery disease, and in neurology to locate abnormal glucose metabolism related to epileptic seizures.